IMGN — ImmunoGen Income Statement
0.000.00%
Last trade - 00:00
- $8.72bn
- $8.22bn
- $108.78m
- 34
- 12
- 95
- 44
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 53.4 | 82.3 | 132 | 69.9 | 109 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 109 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 215 | 174 | 155 | 195 | 330 |
Operating Profit | -161 | -92.2 | -22.4 | -125 | -221 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -169 | -104 | -44.4 | -139 | -222 |
Provision for Income Taxes | |||||
Net Income After Taxes | -169 | -104 | -44.4 | -139 | -223 |
Net Income Before Extraordinary Items | |||||
Net Income | -169 | -104 | -44.4 | -139 | -223 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -169 | -104 | -44.4 | -139 | -223 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.18 | -0.558 | -0.243 | -0.676 | -0.879 |